BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 14961040)

  • 41. Use of oligonucleotide probes directed against T cell antigen receptor gamma delta variable-(diversity)-joining junctional sequences as a general method for detecting minimal residual disease in acute lymphoblastic leukemias.
    Macintyre EA; d'Auriol L; Duparc N; Leverger G; Galibert F; Sigaux F
    J Clin Invest; 1990 Dec; 86(6):2125-35. PubMed ID: 2174915
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
    Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
    Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pattern of T-cell receptor delta gene rearrangement by Southern blotting and polymerase chain reaction technique in Hong Kong Chinese patients with non-T-cell hematological malignancies.
    Chan DW; Liang R; Kwong YL
    Hematol Oncol; 1996 Jun; 14(2):57-66. PubMed ID: 8876635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DHPLC based fraction collection of TCR-gamma rearrangements in childhood ALL: direct sequencing of products amplified by a single or a multiplex PCR approach.
    Zur Stadt U; Isbarn H; Schneppenheim R; Kabisch H
    Int J Oncol; 2005 Aug; 27(2):547-52. PubMed ID: 16010438
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
    Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
    Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes.
    Eckert C; Scrideli CA; Taube T; Songia S; Wellmann S; Manenti M; Seeger K; Biondi A; Cazzaniga G
    Leukemia; 2003 Dec; 17(12):2517-24. PubMed ID: 14562127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle.
    Brüggemann M; Gökbuget N; Kneba M
    Semin Oncol; 2012 Feb; 39(1):47-57. PubMed ID: 22289491
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
    Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
    Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
    Guggemos A; Eckert C; Szczepanski T; Hanel C; Taube T; van der Velden VH; Graf-Einsiedel H; Henze G; Seeger K
    Haematologica; 2003 Jul; 88(7):737-46. PubMed ID: 12857551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Consensus JH gene probes with conjugated 3'-minor groove binder for monitoring minimal residual disease in acute lymphoblastic leukemia.
    Uchiyama M; Maesawa C; Yashima-Abo A; Tarusawa M; Endo M; Sugawara W; Chida S; Onodera S; Tsukushi Y; Ishida Y; Tsuchiya S; Masuda T
    J Mol Diagn; 2005 Feb; 7(1):121-6. PubMed ID: 15681483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease.
    Breit TM; Beishuizen A; Ludwig WD; Mol EJ; Adriaansen HJ; van Wering ER; van Dongen JJ
    Leukemia; 1993 Dec; 7(12):2004-11. PubMed ID: 8255100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improved detection of minimal residual leukemia through modifications of polymerase chain reaction analyses based on clonospecific T cell receptor junctions.
    Seriu T; Hansen-Hagge TE; Erz DH; Bartram CR
    Leukemia; 1995 Feb; 9(2):316-20. PubMed ID: 7869770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. T-cell receptor gamma and delta gene rearrangements and junctional region characteristics in south Indian patients with T-cell acute lymphoblastic leukemia.
    Sudhakar N; Nancy NK; Rajalekshmy KR; Ramanan G; Rajkumar T
    Am J Hematol; 2007 Mar; 82(3):215-21. PubMed ID: 17133429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
    van der Velden VH; Cazzaniga G; Schrauder A; Hancock J; Bader P; Panzer-Grumayer ER; Flohr T; Sutton R; Cave H; Madsen HO; Cayuela JM; Trka J; Eckert C; Foroni L; Zur Stadt U; Beldjord K; Raff T; van der Schoot CE; van Dongen JJ;
    Leukemia; 2007 Apr; 21(4):604-11. PubMed ID: 17287850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Neale GA; Coustan-Smith E; Stow P; Pan Q; Chen X; Pui CH; Campana D
    Leukemia; 2004 May; 18(5):934-8. PubMed ID: 15029212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
    Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
    Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IgH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL.
    Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; von dem Borne AE; van der Schoot CE
    Leukemia; 1995 Jan; 9(1):216-22. PubMed ID: 7845021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukaemia by single-strand conformation polymorphism studies and highly resolutive PCR derived methods: implication for a general strategy of minimal residual disease detection.
    Baruchel A; Cayuela JM; MacIntyre E; Berger R; Sigaux F
    Br J Haematol; 1995 May; 90(1):85-93. PubMed ID: 7786801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Denys B; van der Sluijs-Gelling AJ; Homburg C; van der Schoot CE; de Haas V; Philippé J; Pieters R; van Dongen JJ; van der Velden VH
    Leukemia; 2013 Mar; 27(3):635-41. PubMed ID: 22945774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.